Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 55Other hematologic neoplasm 35Plasma cell 4Myeloid 3CNS 3Tumor-Agnostic 2Genitourinary 1Dermatologic 1Classical hematology 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × ibrutinib × Tumor-Agnostic × Clear all
NCT03525925 2024-03-18

Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01704963 2018-02-05

A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms

Janssen Pharmaceutical K.K.

Phase 1 Completed
15 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡